Innovir Biosciences Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 12-12-2024
- Paid Up Capital ₹ 0.50 M
as on 12-12-2024
- Company Age 7 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue 11.75%
(FY 2022)
- Profit 23.20%
(FY 2022)
- Ebitda 142.46%
(FY 2022)
- Net Worth -11.29%
(FY 2022)
- Total Assets -44.70%
(FY 2022)
About Innovir Biosciences
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Noothy Venkatesham, Santhoshalaxmi Mahamkali, Govardhanreddy Kundur, and One other member serve as directors at the Company.
- CIN/LLPIN
U24100TG2017PTC121328
- Company No.
121328
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Dec 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Innovir Biosciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Govardhanreddy Kundur  | Director | 26-Aug-2021 | Current |
| Noothy Venkatesham | Director | 26-Aug-2021 | Current |
| Santhoshalaxmi Mahamkali | Director | 23-Feb-2024 | Current |
| Pranitha Kodoor | Director | 26-Aug-2021 | Current |
Financial Performance of Innovir Biosciences.
Innovir Biosciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 11.75% increase. The company also saw a substantial improvement in profitability, with a 23.2% increase in profit. The company's net worth observed a substantial decline by a decrease of 11.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Innovir Biosciences?
Unlock access to Innovir Biosciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Refulgent Technologies India Private LimitedActive 2 years 3 months
Pranitha Kodoor is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Innovir Biosciences?
Unlock and access historical data on people associated with Innovir Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Innovir Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Innovir Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
